Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
N/A
1(20.0%)
5Total
Phase 1(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03514537Not ApplicableSuspended

Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes

Role: collaborator

NCT02946658Phase 1Suspended

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

Role: collaborator

NCT02849470Phase 1Withdrawn

AGA Biocellular Stem/Stromal Hair Regenerative Study

Role: collaborator

NCT02952131Phase 1Suspended

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Role: collaborator

NCT02961114Phase 1Withdrawn

Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy

Role: collaborator

All 5 trials loaded